Intra-arterial Drug Therapy for Cerebral Vasospasm (iVAST Trial)

"Affirmative, the clinical trial is actively searching for patients. It was posted on August 29th 2016 and last updated on December 15 2021; it requires 330 participants from 3 medical centres."

"Applicants who meet the criteria of this medical study must be between 18 and 80 years old. For those below 18, there are 2 clinical trials available; for senior citizens over 65, 25 studies have been launched."

"This research project is engaging 330 participants, aged between 18 and 80, who suffer from cerebral vasospasm. The prerequisite qualifications for involvement in the study include being an adult patient of age 18-80 years old with a ruptured aneurysm(s) experiencing symptomatic vasospasm (clinical or TCD), as well as having developed said condition within 3 to 21 days post operatively."

"Nicardipine was initially studied in 2009 at Seoul National University Bundang Hospital. Since then, 157 clinical trials have been conducted and 15 are currently underway - the majority of them being based out of Manhasset, New york."

"Nicardipine is a common medication used to manage the symptoms of angina pectoris. This drug can also provide relief for those suffering from atrial fibrillation, flutter and unstable angina pectoris."

"This clinical trial is actively on the lookout for participants. It was first posted in August of 2016 and most recently revised at the end of December 2021, according to information available from clinicaltrials.gov."

"Nicardipine is categorized as safe by our team at Power, since it has reached Phase 4 of clinical trials and therefore been given approval. This safety rating was assigned a score of 3."